Brendan Lucey
Washington University School of Medicine · Washington Univeristy School of Medicine · Washington University Medical School
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brendan Lucey as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06274528 · DORA and LP in Alzheimer's Disease BiomarkersUniversity of Minnesota · recruiting · Alzheimer Disease · principal investigator
- Ph2NCT05728736 · Acute Effect of Lemborexant on CSF Amyloid-Beta and TauBrendan Lucey · withdrawn · Alzheimer Disease · principal investigator
- Ph2NCT04629547 · Sleep Trial to Prevent Alzheimer's DiseaseUniversity of Minnesota · recruiting · Sleep, Alzheimer Disease · principal investigator
- N/ANCT03077620 · Sleep Quality and Amyloid-Beta KineticsWashington University School of Medicine · completed · Amyloid-beta · principal investigator
- N/ANCT02063217 · Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep InductionWashington University School of Medicine · completed · Amyloid-beta · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Effect of Suvorexant on Alzheimer's Disease BiomarkersR01AG080551 · NIA · WASHINGTON UNIVERSITY · fiscal years 2023 to 2024 · $1,504,459 awarded in 2024Grant number is on one of their registry trials
- Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer's DiseaseP01AG003991 · NIA · WASHINGTON UNIVERSITY · fiscal years 2019 to 2023 · $216,019 awarded in 2023Same name and institution; not confirmed by an ID
- Characterization of Orexin/Hypocretin Kinetics in Alzheimer's DiseaseR21AG074151 · NIA · WASHINGTON UNIVERSITY · fiscal years 2021 to 2022 · $196,875 awarded in 2022Same name and institution; not confirmed by an ID
- Sleep Quality and Human Amlyoid-Beta KineticsK76AG054863 · NIA · WASHINGTON UNIVERSITY · fiscal years 2016 to 2020 · $155,742 awarded in 2020Same name and institution; not confirmed by an ID
- SLEEP: A POTENTIAL NOVEL MODULATOR OF ALZHEIMER'S DISEASE PATHOLOGYR03AG047999 · NIA · WASHINGTON UNIVERSITY · fiscal years 2014 to 2015 · $110,943 awarded in 2015Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Core C: Data Management and Statistical CoreP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI CHENGJIE XIONG · fiscal years 1985 to 2019Named on NCT02063217
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:49 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Comparison of a single-channel EEG sleep study to polysomnography.J Sleep Res · 2016117 citationsRCR 5.8
- 115 citationsRCR 6.1
- 92 citationsRCR 11.5
- Abdominal 64-MDCT for suspected appendicitis: the use of oral and IV contrast material versus IV contrast material only.AJR Am J Roentgenol · 200966 citationsRCR 3.0
- An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.Alzheimers Res Ther · 201526 citationsRCR 0.9
- Increased Cerebrospinal Fluid Amyloid-β During Sleep Deprivation in Healthy Middle-Aged Adults Is Not Due to Stress or Circadian Disruption.J Alzheimers Dis · 202023 citationsRCR 1.2
- A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease.Alzheimers Res Ther · 202416 citationsRCR 2.9
- Influence of body habitus and use of oral contrast on reader confidence in patients with suspected acute appendicitis using 64 MDCT.Emerg Radiol · 201014 citationsRCR 0.6